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GABAA receptors are the primary inhibitory ion chan-
nels in the mammalian central nervous system. The
A322D mutation in the a1 subunit of GABAA recep-
tors is known to result in its degradation and reduce
its cell surface expression, leading to loss of GABAA
receptor function in autosomal dominant juvenile
myoclonic epilepsy. Here, we show that SAHA, a
FDA-approved drug, increases the transcription of
the a1(A322D) subunit, enhances its folding and traf-
ficking posttranslationally, increases its cell surface
level, and restores the GABA-induced maximal cur-
rent in HEK293 cells expressing a1(A322D)b2g2
receptors to 10% of that for wild-type receptors. To
enhance the trafficking efficiency of the a1(A322D)
subunit, SAHA increases the BiP protein level and
the interaction between the a1(A322D) subunit and
calnexin. SAHA is a drug that enhances epilepsy-
associated GABAA receptor proteostasis.
INTRODUCTION
The maintenance of protein homeostasis (proteostasis) in each
subcellular compartment is necessary for maintaining normal
organismal physiology (Balch et al., 2008; Hartl et al., 2011).
The capacity and throughput of the proteostasis network needs
to be adjusted to achieve a delicate balance between protein
synthesis, folding, and trafficking versus degradation while mini-
mizing misfolding and aggregation (Gidalevitz et al., 2011;
Hebert et al., 2010; Lindquist, 1986; Schro¨der and Kaufman,
2005; Smith et al., 2011; Vembar and Brodsky, 2008; Walter
and Ron, 2011). Excessive protein misfolding and degradation
lead to numerous loss-of-function diseases (Guerriero and Brod-
sky, 2012; Hebert and Molinari, 2007).
Approximately one-third of the eukaryotic proteome, including
the membrane proteome, is folded in the endoplasmic reticulum
(ER). Ion channel proteins, including GABAA receptors, are
cotranslationally translocated onto the ER membrane for folding
and assembly (Alder and Johnson, 2004; Green andMillar, 1995;
Skach, 2009). Cellular folding of ion channels requires the
engagement of both the ER and the cytosolic folding machin-
eries because ion channels contain both the ER lumenal and
cytosolic components (Braakman and Bulleid, 2011; Bukau1456 Chemistry & Biology 20, 1456–1468, December 19, 2013 ª2013et al., 2006; Deuerling and Bukau, 2004; Frydman, 2001; Hartl
and Hayer-Hartl, 2002). The BiP system and the calnexin/calre-
ticulin system are the two major chaperone systems in the ER
(Braakman and Bulleid, 2011; Dudek et al., 2009; Hebert and
Molinari, 2012; Hebert et al., 1995; Helenius and Aebi, 2004;
Otero et al., 2010; Rutkevich and Williams, 2011). BiP (also
termed Grp78, Gene name: HSPA5) belongs to the heat shock
protein 70 kDa (Hsp70) family. BiP binds to the hydrophobic
patches of unfolded proteins, facilitating their folding while pre-
venting aggregation (Dudek et al., 2009; Flynn et al., 1991; Otero
et al., 2010; Simons et al., 1995). However, in association with its
co-chaperones, such as ERdj4 or ERdj5, BiP may direct termi-
nally misfolded proteins to the cellular degradation pathway
(Dong et al., 2008; Dudek et al., 2009; Otero et al., 2010; Ushioda
et al., 2008). Upon entering the ER, proteins are glycosylated on
Asn residues (in the context of an Asn-X-Ser/Thr sequencemotif)
and attached with the core oligosaccharide Glc3Man9GlcNAc2,
where Glc is glucose, Man is mannose, and GlcNAc is N-acetyl-
glucosamine. This N-linked core oligosaccharide serves as a tag
for protein maturation (Hebert and Molinari, 2012; Helenius and
Aebi, 2004). Calnexin, a membrane bound lectin chaperone,
and its soluble ortholog calreticulin assist N-linked glycoprotein
folding in the ER with the assistance of protein disulfide isomer-
ases (PDIs; Helenius et al., 1997; Rutkevich and Williams, 2011).
Although BiP and calnexin were reported to interact with the a1
subunit of GABAA receptors (Connolly et al., 1996), their role in
assisting GABAA receptor folding and trafficking was not
explored. Properly folded and assembled ion channels will be
exported out of the ER and trafficked to the Golgi, where ion
channels undergo additional complex glycosylation events and
ultimately reach the plasma membrane in a fully functional state.
In the case of misfolded ion channels, the ER quality control
machinery recognizes and targets them for the ER-associated
degradation (ERAD) pathway, where misfolded ion channels
are retrotranslocated into the cytosol and degraded by the pro-
teasome (Vembar and Brodsky, 2008).
GABAA receptors are the major inhibitory neurotransmitter-
gated ion channels in the human brain (Macdonald and Olsen,
1994) and belong to the Cys-loop receptor superfamily (Lester
et al., 2004). GABAA receptors are pentameric, sharing common
structural characteristics with other Cys-loop receptor members
(Dougherty, 2008). The most common GABAA receptor type in
the human brain is a heteropentamer, containing two a, two b,
and one g subunits. Each subunit has four transmembrane
(TM) helices (TM1–TM4, with the TM2 domain lining the interior
of the pore); a large extracellular (or the ER lumenal) N terminus;
and an extracellular (or the ER lumenal) C terminus. EachElsevier Ltd All rights reserved
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sites. Each GABA binding site lies between one a1 subunit and
its adjacent b2 subunit and occupies the N-terminal extracellular
domain.
The missense A322D mutation in the TM3 domain of the a1
subunit of GABAA receptors leads to autosomal dominant juve-
nile myoclonic epilepsy (ADJME), a common form of idiopathic
generalized epilepsy representing 5%–10% of all epilepsy cases
(Cossette et al., 2002). The A322Dmutation in the a1 subunit was
reported to result in the misfolding of the a1(A322D) subunit,
which led to rapid degradation of the a1(A322D) subunit mainly
by the ER-associated degradation pathway (Gallagher et al.,
2007), although the misfolded a1(A322D) subunit might be alter-
natively targeted to the lysosome for degradation (Bradley et al.,
2008). The consequence is that few a1(A322D) subunits are
transported to the plasmamembrane, reducing the level of func-
tional heteropentameric GABAA receptors in the cell membrane.
As a consequence, the A322D mutation leads to substantially
reduced GABA-induced current in electrophysiological experi-
ments. In the case of the few mutant receptors that reach the
plasma membrane, they generate GABA-induced currents with
different electrophysiological properties compared to wild-type
(WT) receptors (Krampfl et al., 2005; Lachance-Touchette
et al., 2011).
We hypothesized that we could enhance the folding and/or
trafficking and thus restore function in the case of epilepsy-asso-
ciated mutant a1(A322D)b2g2 GABAA receptors. A number of
proteostasis regulators (Balch et al., 2008) were reported to cor-
rect protein misfolding diseases such as cystic fibrosis and lyso-
somal storage diseases (Hutt et al., 2010; Mu et al., 2008). Thus,
we tested whether such small molecules could enhance proteo-
stasis of a1(A322D)b2g2 GABAA receptors. We showed that
suberoylanilide hydroxamic acid (SAHA) and trichostatin A
(TSA), potent histone deacetylase (HDAC) inhibitors, increased
the total protein level of the a1(A322D) subunit. Our data indicate
that SAHA, a FDA-approved drug that crosses the blood-brain
barrier (Hockly et al., 2003), increased the transcription,
enhanced the folding and trafficking, and partially corrected
function of epilepsy-associated a1(A322D)b2g2 GABAA recep-
tors, thus representing a potential avenue for the treatment of
ADJME that results from GABAA receptor misfolding.
RESULTS
SAHA Increases the Total Protein Level of a1(A322D)
b2g2 GABAA Receptors
The A322D mutation in the a1 subunit was reported to decrease
both the total and cell surface expression of the a1(A322D) sub-
unit mainly by ERAD (Gallagher et al., 2007). We tested small
molecules that were reported to rescue misfolded proteins in
the literature, including celastrol, a potent heat shock response
activator; SAHA and TSA, potent HDAC inhibitors; and curcumin
and thapsigargin, ER Ca2+ signaling pathway regulators, for their
potential to rescue functional GABAA receptor expression.
HEK293 cells stably expressing a1(A322D)b2g2 GABAA recep-
tors were treated with celastrol (0.5 mM), SAHA (2.5 mM), TSA
(0.5 mM), curcumin (1 mM), or thapsigargin (0.5 mM) for 24 hr.
Western blot analysis showed that both SAHA and TSA, but
not other small molecules, significantly increased the total pro-Chemistry & Biology 20, 1456–146tein level of the a1(A322D) subunit (Figure S1A available online).
The different effect between SAHA/TSA and other small mole-
cules might be due to their different regulation of GABAA recep-
tor binding chaperones. Dose-response analysis of SAHA (24 hr)
showed that SAHA increased the total a1(A322D) subunit signif-
icantly at as low as 0.5 mM, and the saturation effect of SAHAwas
achieved at 2.5 mM (Figure S1B). Time-course study showed that
SAHA’s effect on increasing total a1(A322D) subunit was
achieved as early as 4 hr and maximized at 24 hr; longer SAHA
treatment didn’t further increase total a1(A322D) subunit, which
might be due to the instability of SAHA in cell culture media
(Figure S1C). SAHA treatment (2.5 mM, 24 hr) or TSA treatment
(0.5 mM, 24 hr) increased the total protein levels of a1, b2,
and g2 subunits in HEK293 cells expressing either WT or
a1(A322D)b2g2 GABAA receptors (Figure 1A; see Figure 1B for
quantification). The total protein level of the a1(A322D) subunit
is 25% of that of theWT a1 subunit because the A322Dmutation
resulted in extensive ERAD of the a1(A322D) subunit (Figure 1B).
In HEK293 cells expressing a1(A322D)b2g2 GABAA receptors,
SAHA treatment (2.5 mM, 24 hr) increased the total protein level
of the a1(A322D) subunit by 5.0-fold, the b2 subunit by 2.0-fold,
and the g2 subunit by 1.4-fold, whereas TSA treatment (0.5 mM,
24 hr) increased the total protein level of the a1(A322D) subunit
by 3.0-fold, the b2 subunit by 2.7-fold, and the g2 subunit by
1.9-fold (Figure 1B). An increase in WT a1, b2, or g2 subunits
afforded by SAHA treatment might be due to inefficient folding
and trafficking or an increase in the synthesis of WT subunits.
However, a more dramatic increase of the total protein was
observed in HEK293 cells expressing a1(A322D) subunits than
that expressingWT a1 subunits, possibly because SAHA’s effect
is more dramatic on misfolding-prone a1(A322D) subunits. An
MTT cell toxicity assay showed that SAHA treatment (2.5 mM,
24 hr) of the HEK293 cells expressing either WT or a1(A322D)
b2g2 GABAA receptors did not substantially reduce the cell
viability (Figure S1D), consistent with the fact that SAHA is
well-tolerated in the clinical trial (Kelly et al., 2003). Quantitative
RT-PCR experiment showed that SAHA treatment (2.5 mM,
24 hr) increased the mRNA level of the a1(A322D) subunit by
3.8-fold in HEK293 cells stably expressing a1(A322D)b2g2
GABAA receptors (Figure S1E), indicating that SAHA treatment
increased the protein synthesis load of the a1(A322D) subunit,
partially contributing to the 5.0-fold increase of the protein level
of the a1(A322D) subunit.
SAHA Enhances the Folding and Trafficking and
Reduces the ERAD of the a1(A322D) Subunit
Posttranslationally
To determinewhether the increased total a1(A322D) subunit pro-
tein after SAHA treatment folded properly in the ER, we treated
the cell lysates with endoglycosidase H (endo H) enzyme and
then analyzed them using western blot. The endo H enzyme
selectively cleaves after asparaginyl-N-acetyl-D-glucosamine
in the N-linked glycans incorporated on the a1 subunit in the
ER, but it is not possible to remove this oligosaccharide chain
after the high-mannose form is enzymatically remodeled in the
Golgi. Therefore, endo H resistant a1 subunit bands represent
properly folded, post-ER a1 subunit glycoforms, which traffic
at least to the Golgi compartment. The peptide-N-glycosidase
F (PNGase F) enzyme cleaves between the innermost GlcNAc8, December 19, 2013 ª2013 Elsevier Ltd All rights reserved 1457
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SAHA Enhances Mutant GABAA Receptor Proteostasisand asparagine residues from N-linked glycoproteins, serving as
a control for unglycosylated a1 subunits (Figure 1C, lane 5). After
endo H digestion, subunits with a molecular weight equal to un-
glycosylated a1 subunits were considered endo H-sensitive,
whereas those with higher molecular weight were considered
endo H-resistant (Figure 1C, lanes 2, 4, 7, and 9). There are
two endo H-resistant bands because the a1 subunit has two
glycosylation sites (Asn38 and Asn138) in the ER. This is consis-
tent with a report of the endo H-resistant b2 subunits (Lo et al.,
2010). The upper two endo H-resistant a1(A322D) subunit bands
are 23% of those of the WT a1 subunit (Figure 1C, cf. lane 7 to
lane 2). SAHA treatment (2.5 mM, 24 hr) in HEK293 cells stably
expressing a1(A322D)b2g2 GABAA receptors clearly increased
the upper two endo H-resistant a1(A322D) subunit bands (Fig-
ure 1C, cf. lane 9 to lane 7), indicating that SAHA treatment
increased properly folded, post-ER glycoforms of
the a1(A322D) subunit. The ratio of endo H resistant/total
a1(A322D) serves as a measure of trafficking efficiency of the
a1(A322D) subunit. SAHA treatment (2.5 mM, 24 hr) significantly
increased the ratio of endo H resistant/total a1(A322D) (Fig-
ure 1C, cf. lane 9 to lane 7, see Figure 1D for quantification), indi-
cating that SAHA treatment increased trafficking efficiency of the
a1(A322D) subunit.
Furthermore, we used cycloheximide (CHX)-chase experi-
ments to quantify whether SAHA influenced the degradation
rate of the a1(A322D) subunit. The a1(A322D) subunit has a
half-life of 40 min when fitted to a single exponential function
(Figure 1E), consistent with the reported [35S]methionine-chase
result (Bradley et al., 2008; Gallagher et al., 2007). SAHA treat-
ment (2.5 mM, 24 hr) increased the half-life of the a1(A322D) sub-
unit from 40 to 125min (Figure 1E), indicating that SAHA reduced
the degradation of the a1(A322D) subunit. To determine whether
SAHA influenced the proteasome degradation of the a1(A322D)
subunit, HEK293 cells stably expressing a1(A322D)b2g2 GABAA
receptors were immunoprecipitated using anti-a1 antibody and
blotted for ubiquitin. SAHA treatment (2.5 mM, 24 hr) clearly
decreased the intensity of ubiquitinated a1(A322D) subunitFigure 1. SAHA Enhances the Folding and Trafficking of the a1(A322D
b2g2 GABAA Receptors
(A and B) SAHA (2.5 mM, 24 hr) or TSA (0.5 mM, 24 hr) increases the total protein le
a1(A322D)b2g2 GABAA receptors (n = 3) (A). The chemical structures of SAHA and
(C and D) SAHA (2.5 mM, 24 hr) increases the endo H-resistant post-ER glycoform
b2g2 GABAA receptors (n = 3) (C). PNGase F treatment serves as a control for u
a1subunit bands is shown in (D).
(E) SAHA (2.5 mM, 24 hr) decreases the degradation rate of the a1(A322D) subu
cycloheximide (CHX) pulse-chase analysis.
(F) SAHA (2.5 mM, 24 hr) decreases ubiquitinated a1(A322D) subunit in HEK293
(G) SAHA (2.5 mM, 24 hr) increases the a1(A322D) subunit surface expression in H
immunofluorescence analysis (n = 3).
(H) SAHA (2.5 mM, 24 h) increases the surface protein expression of the a1 subunit
b2g2 GABAA receptors according to surface biotinylation analysis (n = 3).
(I and J) An increased protein synthesis load of the misfolding-prone a1(A322D) su
HEK293 cells were transiently transfected with 0.2 or 1.0 mg of a1(A322D) plasmids
with SAHA (2.5 mM, 24 hr) together with same amount of b2 and g2 subunit plasmid
(J). Because of the large dynamic range of blot intensity, for clear visualization, we
efficiency of the a1(A322D) subunit under three different conditions. We used the
appropriate exposure.
(K) SAHA (2.5 mM) increases the mRNA level of the a1(A322D) subunit significantl
analysis in HEK293 cells expressing a1(A322D)b2g2 GABAA receptors. NS, not s
(L and M) SAHA (2.5 mM) increases the ratio of endo H resistant/total a1(A322D) s
Each data point in (B), (D), (E), (H), (J), (K), and (M) is reported as mean ± SEM. *
Chemistry & Biology 20, 1456–146(Figure 1F), indicating that SAHA reduced the ERAD of the
a1(A322D) subunit. To determine whether SAHA influenced the
lysosomal degradation of the a1(A322D) subunit, we used a
lysosomal protease inhibitor leupeptin with or without SAHA in
HEK293 cells stably expressing a1(A322D)b2g2 GABAA recep-
tors. Leupeptin treatment (25 mM, 24 hr) increased the total pro-
tein level of the a1(A322D) subunit (Figure S1F), consistent with a
literature report that the lysosome is involved in the degradation
of the a1(A322D) subunit (Bradley et al., 2008). Co-application
of SAHA and leupeptin produced slightly synergistic effect to
increase the total protein level of the a1(A322D) subunit (Fig-
ure S1F), indicating that SAHA did not influence the lysosomal
degradation of the a1(A322D) subunit. To determine whether
SAHA influenced the endocytosis of the a1(A322D) subunit, we
used a dynamin 1 inhibitor dynole 34-2 with or without SAHA in
HEK293 cells stably expressing a1(A322D)b2g2 GABAA recep-
tors. Dynole 34-2 treatment (2.5 mM, 24 hr) increased the surface
a1(A322D) subunit (Figure S1G), consistent with a literature
report that the a1(A322D) subunit undergoes dynamin-1 depen-
dent endocytosis on the plasmamembrane (Bradley et al., 2008).
Co-application of SAHA and dynole 34-2 produced additive
effect to increase the surface a1(A322D) subunit (Figure S1G),
indicating that SAHA did not influence the dynamin-1 dependent
endocytosis of the a1(A322D) subunit.
To determine whether properly folded a1(A322D) subunits
after SAHA treatment were successfully trafficked to the plasma
membrane, we performed an indirect immunofluorescence
microscope experiment. The application of the anti-a1 antibody
without a prior membrane permeabilization step enables us to
visualize the cell surface a1 subunit. In HEK293 cells expressing
WT GABAA receptors, as expected, a substantial amount of a1
subunit staining was observed for both total a1 subunit (Fig-
ure 1G, top row, green) and cell surface a1 subunit (Figure 1G,
top row, red). The merge between the total a1 subunit and cell
surface a1 subunit is colored yellow (Figure 1G, third column).
The A322D mutation led to very weak total a1 subunit staining
(Figure 1G, second row, green) and essentially no cell surface) Subunit in Cells Stably Expressing Epilepsy-Associated a1(A322D)
vel of a1, b2, and g2 subunits in HEK293 cells stably expressing WT a1b2g2 or
TSA are shown on left of (A). Quantification is shown in (B). IB, immunoblotting.
of the a1 subunit in HEK293 cells stably expressing WT a1b2g2 or a1(A322D)
nglycosylated a1 subunit. Quantification of the ratio of endo H-resistant/total
nit in HEK293 cells stably expressing a1(A322D)b2g2 GABAA receptors using
cells stably expressing a1(A322D)b2g2 GABAA receptors.
EK293 cells stably expressing a1(A322D)b2g2 GABAA receptors using indirect
in HEK293 cells and SH-SY5Y cells stably expressingWT a1b2g2 or a1(A322D)
bunit does not lead to increased trafficking efficiency of the a1(A322D) subunit.
for 48 hr or transfectedwith 0.2 mg of a1(A322D) plasmids for 48 hr and treated
s before being lysed for endo H digestion analysis (I). Quantification is shown in
put the same blot under three different exposure times to quantify the trafficking
three black-boxed regions in Figure 1I to achieve accurate quantification with
y after 8 hr treatment, but not before 6 hr treatment using quantitative RT-PCR
ignificant.
ubunit significantly as early as 3 hr treatment (L). Quantification is shown in (M).
p < 0.05
8, December 19, 2013 ª2013 Elsevier Ltd All rights reserved 1459
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GABA-Induced Chloride Currents in HEK293 Cells Expressing
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Representative whole-cell patch clamping recording traces in HEK293 cells
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quantification of the peak currents is shown in (B). Each point is reported as
mean ± SEM. **p < 0.01
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SAHA Enhances Mutant GABAA Receptor Proteostasisa1 subunit staining (Figure 1G, second row) because of exten-
sive ERAD. SAHA treatment (2.5 mM, 24 hr) resulted in a dramatic
increase in both total a1(A322D) subunit staining (Figure 1G, third
row, green) and cell surface a1(A322D) subunit staining (Fig-
ure 1G, third row, red), indicating that SAHA treatment enhanced
the trafficking of the a1(A322D) subunit to the cell surface.
We further confirmed and quantified the increased cell surface
a1 subunit level using cell surface biotinylation and Western blot
analysis. SAHA treatment (2.5 mM, 24 hr) increased the surface
a1(A322D) subunit level 5.0-fold (to 49% of the surface WT a1
subunit level) in HEK293 cells and 11.5-fold (to 137% of the
surface WT a1 subunit level) in SH-SY5Y cells expressing
a1(A322D)b2g2 GABAA receptors (Figure 1H). SAHA treatment
(2.5 mM, 24 hr) also modestly increased the surface WT a1 sub-
unit in HEK293 cells or SH-SY5Y cells stably expressing WT
a1b2g2 GABAA receptors (Figure 1H). This might be due to an
increase of the synthesis or an enhanced trafficking of WT a1
subunit.
To show that an increased trafficking efficiency of the misfold-
ing-prone a1(A322D) subunit was due to SAHA’s effect post-
translationally and not from an increased protein synthesis
load, we carried out the following experiments. HEK293 cells
were transiently transfected with 0.2 mg or 1.0 mg of a1(A322D)
plasmids for 48 hr, or transfected with 0.2 mg of a1(A322D) plas-
mids for 48 hr and treated with SAHA for 24 hr before being lysed
for endo H digestion analysis. Using these two plasmid amounts
was led by a previous report, showing that the total a1(A322D)
subunit protein expression level increased linearly with the trans-
fected a1(A322D) plasmids from 0 to 2 mg (Ding et al., 2010). We
observed that HEK293 cells transfected with 1.0 mg of a1(A322D)
plasmids led to more total a1(A322D) protein load than HEK293
cells transfected with 0.2 mg of a1(A322D) plasmids in the pres-
ence or absence of SAHA (Figure 1I, cf. lane 5 to lane 3 and lane1460 Chemistry & Biology 20, 1456–1468, December 19, 2013 ª20131). However, the ratio of endo H resistant/total a1(A322D) in
HEK293 cells did not increase due to increased amount of trans-
fected plasmids (i.e., 0.2–1.0 mg; Figure 1I, cf. lane 6 to lane 2,
see Figure 1J for quantification), indicating that increasing pro-
tein synthesis load of the a1(A322D) subunit did not increase traf-
ficking efficiency of the a1(A322D) subunit. This was consistent
with a previous report, showing that increasing protein synthesis
load of a1(A322D) subunit did not increase its cell surface
expression (Ding et al., 2010). Furthermore, an increased traf-
ficking efficiency of the a1(A322D) subunit afforded by SAHA
treatment in HEK293 cells transfected with 0.2 mg of a1(A322D)
plasmids was in sharp contrast to the unincreased trafficking
efficiency in HEK293 cells transfected with 1.0 mg of a1(A322D)
plasmids (Figure 1I, cf. lane 4 to lane 6, see Figure 1J for quan-
tification), indicating that SAHA’s effect on enhancing the
trafficking efficiency of the a1(A322D) subunit was indeed a
posttranslational effect instead of due to increased protein syn-
thesis load of the a1(A322D) subunit.
A time-course study showed that SAHA (2.5 mM) increased the
mRNA level of the a1(A322D) subunit significantly after 8 hr treat-
ment, but not before 6 hr treatment using quantitative RT-PCR
analysis in HEK293 cells expressing a1(A322D)b2g2 GABAA
receptors (Figure 1K). However, SAHA (2.5 mM) increased the ra-
tio of endo H resistant/total a1(A322D) subunit significantly as
early as 3 hr treatment (Figure 1L, see Figure 1M for quantifica-
tion), indicating that an increased trafficking efficiency of the
a1(A322D) afforded by SAHA occurred before an increased tran-
scriptional level of the a1(A322D). Similar case was reported:
SAHA did not increase the transcription of DF508 CFTR before
8 hr treatment while SAHA increased mature DF508 CFTR pro-
tein level as early as after 4 hr treatment (Hutt et al., 2010). There-
fore, our result is consistent with SAHA’s effect on increasing the
trafficking efficiency of the misfolding-prone a1(A322D) subunit
posttranslationally.
SAHA Significantly Increases the Peak Amplitude of
GABA-Induced Chloride Currents in HEK293 Cells
Expressing a1(A322D)b2g2 GABAA Receptors
The A322D mutation in the a1 subunit leads to significantly low-
ered peak amplitude of GABA-induced currents in whole-cell
patch-clamp electrophysiological experiments (Krampfl et al.,
2005; Lachance-Touchette et al., 2011). In our whole-cell
patch-clamp experimental setup, dose-response analysis
showed that the half-maximal effective current (EC50) of GABA
was 12.7 ± 4.5 mM (Figure S2) in HEK293 cells expressing WT
a1b2g2 GABAA receptors, consistent with the reported EC50
value of 11.2 ± 0.6 mM (Krampfl et al., 2005). Without drug treat-
ment, the peak current was 1.0 ± 0.4 pA in response to GABA
(3 mM) in HEK293 cells expressing a1(A322D)b2g2 GABAA
receptors, and 138 ± 12 pA in response to GABA (1 mM) in
HEK293 cells expressing WT a1b2g2 GABAA receptors (Fig-
ure 2A). The activation and desensitization kinetics are different
between WT and a1(A322D)b2g2 GABAA receptors, consistent
with the literature report (Krampfl et al., 2005; Lachance-Touch-
ette et al., 2011). SAHA (2.5 mM, 24 hr) treatment significantly
increased the GABA-induced peak current to 14 ± 3 pA in
HEK293 cells expressing a1(A322D)b2g2 GABAA receptors (Fig-
ure 2A), amounting to 10% of the GABA-induced peak current in
HEK293 cells expressingWTGABAA receptors. Quantification ofElsevier Ltd All rights reserved
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Figure 3. SAHA Increases the Protein and
mRNA Level of BiP without an Apparent In-
duction of the XBP1 Splicing
(A and B) SAHA (2.5 mM, 24 hr) only increases the
protein level of BiP among tested major ER and
cytosolic chaperones and ERAD factors in
HEK293 cells stably expressing WT a1b2g2 or
a1(A322D)b2g2 GABAA receptors (n = 3) (A).
Quantification is shown in (B).
(C) SAHA (2.5 mM) increases the mRNA level of BiP
using quantitative RT-PCR analysis.
(D) SAHA (2.5 mM) does not induce the splicing of
XBP1 using RT-PCR analysis. Thapsigargin (Tg) is
used as a positive control to induce XBP1 splicing.
GAPDH is used as a loading control.
Each data point in (B) and (C) is reported asmean ±
SEM. *p < 0.05
Chemistry & Biology
SAHA Enhances Mutant GABAA Receptor Proteostasisthe GABA-induced currents is shown in Figure 2B. These data
indicate that SAHA partially restored the function of epilepsy-
associated a1(A322D)b2g2 GABAA receptors. Acute application
of SAHA (2.5 mM, 1min) in the external perfusion recordingmedia
to HEK293 cells expressing GABAA receptors during the whole-
cell patch-clamp experiment did not significantly change the
GABA-induced peak current (data not shown), indicating that
SAHA did not act as an agonist/antagonist for GABAA receptors
and its function required transcriptional and/or posttranslational
events.
SAHA Increases BiP Level in HEK293 Cells Expressing
a1(A322D)b2g2 GABAA Receptors without an Apparent
Activation of the IRE1 Arm of the Unfolded Protein
Response
We hypothesized that SAHA partially corrects the folding defi-
ciency of the a1(A322D) subunit by regulating the expression
and/or activity of molecular chaperones in the ER and/or the
cytoplasm because the a1(A322D) subunit has both ER lumen
and cytoplasmic domains. We tested whether SAHA treatment
altered the protein level of major molecular chaperones in the
cytoplasm (Hsp70 and Hsp90) and in the ER (calnexin, calreticu-
lin, Grp94, and BiP) and proteins that are involved in the ERAD
pathway (Bag2 and Derlin 1). Only the protein level of BiP was
significantly upregulated by SAHA treatment (2.5 mM, 24 hr):
BiP protein level was increased by 2.7-fold in HEK293 cells
expressing WT GABAA receptors and 2.1-fold in HEK293 cellsChemistry & Biology 20, 1456–1468, December 19, 2013 ªexpressing a1(A322D)b2g2 GABAA re-
ceptors (Figures 3Aand3B). Furthermore,
the mRNA level of BiP was increased
by 5.6-fold in HEK293 cells expressing
WT GABAA receptors and 7.6-fold in
HEK293 cells expressing a1(A322D)b2g2
GABAA receptors after SAHA treatment
(2.5 mM, 24 hr) using quantitative RT-
PCR analysis (Figure 3C), indicating that
SAHA increased the BiP level mainly
through transcriptional regulation.
HSPA5 (gene name of BiP) is an impor-
tant target gene in the activation of the
unfolded protein response (UPR), whichis a well-established ER stress responsive pathway (Schro¨der
and Kaufman, 2005; Walter and Ron, 2011). The ER responds
to the accumulation of unfolded proteins by activating up to
three integrated intracellular signaling pathways (IRE1, ATF6,
and PERK), collectively referred to as the UPR. The UPR regu-
lates the expression of numerous genes comprising the cellular
proteostasis pathways (Adachi et al., 2008; Lee et al., 2003;
Okada et al., 2002). Because HSPA5 is a target of the IRE1
arm of the UPR, we tested whether SAHA treatment increased
BiP mRNA level by activating the IRE1 arm. IRE1 responds to
stress by oligomerization, resulting in trans-autophosphorylation
that activates its endonuclease function, which precisely splices
the mRNA that encodes the transcription factor XBP1 (Schro¨der
and Kaufman, 2005; Walter and Ron, 2011). We used RT-PCR to
detect the spliced form of Xbp-1 in HEK293 cells expressing
a1(A322D)b2g2 GABAA receptors after an incubation with
SAHA (2.5 mM). SAHA treatment did not led to the splicing of
XBP1, indicating no activation of the IRE1 arm of the UPR (Fig-
ure 3D). Used as a positive control, thapsigargin (Tg, 0.5 mM,
6 hr) resulted in XBP1 splicing (Figure 3D, lanes 2 and 6, bottom
band, white pound). Therefore, SAHA used another pathway to
regulate the mRNA level of BiP (see below, and Figure 6C). Tg
(0.5 mM) and tunicamycin (Tm, 10 mg/ ml), potent UPR inducers,
increased the protein level of BiP, but not calnexin (Figures S3A
and S3B), indicating that in HEK293 cells expressing a1(A322D)
b2g2 GABAA receptors, activation of the IRE1 arm did not
increase calnexin protein level.2013 Elsevier Ltd All rights reserved 1461
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Figure 4. SAHA Enhances the Interaction between BiP and the a1 Subunit, and BiP Promotes the a1 Subunit Folding in the ER
(A and B) SAHA treatment (2.5 mM, 24 hr) enhances the interaction between the a1 subunit and BiP in HEK293 cells stably expressing WT a1b2g2 or a1(A322D)
b2g2 GABAA receptors. Quantification of the relative intensity of BiP/a1 is shown in (B).
(C) Reverse immunoprecipitation confirms that SAHA treatment enhances the interaction between the a1(A322D) subunit and BiP.
(D–F) BiP overexpression increases endo H-resistant post-ER glycoform of the a1 subunit (n = 3) (D). PNGase F treatment serves as a control for unglycosylated
a1 subunit. Quantification of the ratio of endo H-resistant/total a1 subunit bands is shown in (E), and quantification of BiP overexpression is shown in (F). EV,
empty vector.
(G–I) BiP knockdown decreases endo H-resistant post-ER glycoform of the a1 subunit (n = 3) (G). Quantification of the ratio of endo H-resistant / total a1 subunit
bands is shown in (H), and quantification of BiP knockdown is shown in (I). NT, nontargeting.
Each data point in (B), (C), (E), (F), (H), and (I) is reported as mean ± SEM. *p < 0.05
Chemistry & Biology
SAHA Enhances Mutant GABAA Receptor ProteostasisSAHA Enhances the Interaction between BiP and the a1
Subunit in the ER, and BiP Promotes GABAA Receptor
Folding and Trafficking
BiP, an abundant ER resident Hsp70 family chaperone, binds to
hydrophobic patches of unfolded proteins and facilitates their
folding while preventing aggregation (Ru¨diger et al., 1997).
Because BiP binds GABAA receptors (Connolly et al., 1996),
which have large ER lumenal components, we continued to
test whether SAHA enhanced the interaction between BiP and
the a1 subunit in the ER. HEK293 cells that express WT or
a1(A322D)b2g2 GABAA receptors were treated with DMSO1462 Chemistry & Biology 20, 1456–1468, December 19, 2013 ª2013vehicle control or SAHA (2.5 mM, 24 hr), and the ER fractions
were enriched. Clearly, SAHA treatment (2.5 mM, 24 hr) signifi-
cantly increased the ratio of immunoprecipitated BiP/a1 by
21-fold in HEK293 cells expressing WT a1b2g2 GABAA recep-
tors and 2.9-fold in HEK293 cells expressing a1(A322D)b2g2
GABAA receptors (Figure 4A, cf. lane 2 to lane 1, and lane 4 to
lane 3, see Figure 4B for quantification), indicating that SAHA
treatment enhanced the interaction between a1 subunits and
BiP in the ER. We also performed a reverse immunoprecipitation
experiment, confirming that SAHA treatment enhanced the inter-
action between the a1(A322D) subunit and BiP (Figure 4C).Elsevier Ltd All rights reserved
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SAHA Enhances Mutant GABAA Receptor ProteostasisHowever, whether an enhanced interaction between BiP and the
a1(A322D) subunit promotes the maturation of the a1(A322D)
subunit merits further study.
Because BiP can either promote its client protein folding
or target its client protein for degradation, we tested how
overexpression or knockdown of BiP influenced the protein
homeostasis of the a1 subunit. A 2.8-fold overexpression of
BiP significantly increased the ratio of endo H-resistant a1/total
a1 subunit by 1.3-fold in HEK293 cells expressing WT a1b2g2
GABAA receptors (Figure 4D, cf. lane 4 to lane 2), and a 2.6-
fold overexpression of BiP significantly increased the ratio of
endo H-resistant a1/total a1 subunit by 3.0-fold in HEK293
cells expressing a1(A322D)b2g2 GABAA receptors (Figure 4D,
cf. lane 9 to lane 7; see Figures 4E and 4F for quantification),
indicating that BiP overexpression increased the trafficking effi-
ciency of the a1 subunit. Knockdown of BiP (69% knockdown
efficiency) clearly decreased the intensity of endo H-resistant
a1(A322D) subunit (Figure 4G, cf. lane 9 to lane 7), and
knockdown of BiP (71% knockdown efficiency) significantly
decreased the ratio of endo H-resistant a1/total a1 subunit (Fig-
ure 4G, cf. lane 4 to lane 2, see Figures 4H and 4I for quantifica-
tion), indicating that BiP knockdown decreased the trafficking
efficiency of the a1 subunit. Therefore, BiP promotes the folding
and maturation of the a1 subunit. Because SAHA increases the
BiP expression (Figure 3A) and BiP overexpression enhances
the maturation of the a1(A322D) subunit (Figure 4D), SAHA
enhances the maturation of the a1(A322D) subunit by increasing
the BiP level.
SAHA Enhances the Interaction between Calnexin and
the a1 Subunit, and Calnexin Promotes GABAA Receptor
Folding and Trafficking in a Glycan-Dependent Way
Because the a1 subunit is a glycoprotein and calnexin (CNX)
and calreticulin are major lectin chaperones in the ER that
assist glycosylated protein folding (Helenius et al., 1997), we
tested whether the folding of the a1 subunit was facilitated
by calnexin and/or calreticulin in addition to BiP in the ER.
Although SAHA did not increase the protein level of calnexin
or calreticulin (Figure 3A), we hypothesized that SAHA
increased the interaction between the a1 subunit and calnexin
and/or calreticulin to enhance the folding of the a1 subunit.
Using enriched ER fractions for immunoprecipitation, SAHA
treatment (2.5 mM, 24 hr) significantly increased the ratio of
immunoprecipitated calnexin/a1 by 3.3-fold in HEK293 cells
expressing WT a1b2g2 GABAA receptors and 1.5-fold in
HEK293 cells expressing a1(A322D)b2g2 GABAA receptors
(Figure 5A, cf. lane 2 to lane 1, and lane 4 to lane 3, see Fig-
ure 5B for quantification), indicating that SAHA treatment
enhanced the interaction between the a1 subunit and calnexin.
We also performed a reverse immunoprecipitation experiment,
confirming that SAHA treatment enhanced the interaction
between the a1(A322D) subunit and calnexin (Figure 5C). How-
ever, an interaction was not detected between the a1(A322D)
subunit and endogenous calreticulin or overexpressed HA-
tagged calreticulin (Figure S4).
Overexpression of calnexin significantly increased the ratio of
endo H-resistant/total a1 subunit by 1.3-fold in HEK293 cells
expressing WT a1b2g2 GABAA receptors (Figure 5D, cf. lane 4
to lane 2) and 2.7-fold in HEK293 cells expressing a1(A322D)Chemistry & Biology 20, 1456–146b2g2 GABAA receptors (Figure 5D, cf. lane 9 to lane 7; see Fig-
ures 5E and 5F for quantification), indicating that calnexin over-
expression increased the trafficking efficiency of the a1 subunit.
Therefore, calnexin promotes the folding and trafficking of the a1
subunit. To explore how the interaction between calnexin and
the a1(A322D) subunit influences the a1(A322D) subunit folding,
HEK293 cells expressing a1(A322D)b2g2GABAA receptors were
transfected with calnexin or calreticulin for 48 hr and treated with
SAHA (2.5 mM, 24 hr). SAHA treatment significantly increased the
ratio of immunoprecipitated calnexin/a1(A322D) (Figure 5G, cf.
lane 3 to lane 2, see Figure 5H for quantification), whereas no
interaction was detected between the a1(A322D) subunit and
overexpressed HA-tagged calreticulin after SAHA treatment
(Figure S4, lane 3). This is consistent with SAHA’s role in promot-
ing the maturation of the a1(A322D) subunit by enhancing the
interaction between the a1(A322D) subunit and calnexin (also
see below, Figure 5I).
Furthermore, we asked whether calnexin used a glycan-
dependent pathway to promote the a1(A322D) subunit folding
in the ER. Upon entering the ER, at two glycosylation sites
(Asn38 and Asn138), the a1 subunit is attached with the core
oligosaccharide Glc3Man9GlcNAc2. The outmost two glucoses
are removed by glucosidase I and II, which generates
the monoglucosylated oligosaccharide Glc1Man9GlcNAc2, a
substrate for calnexin. The N38Q/N138Q double mutations
in a1(A322D) would prevent a glycan-dependent binding of
calnexin to the N38Q/N138Q mutant a1(A322D) subunit. The
N38Q/N138Q mutant a1(A322D) subunit had a lower molecular
weight than the a1(A322D) subunit (Figure 5I, cf. lane 2 to lane
1), presumably due to loss of glycans. The N38Q/N138Q muta-
tions significantly decreased the ratio of immunoprecipitated
calnexin/a1(A322D) in HEK293 cells (Figure 5I, cf. lane 2 to
lane 1, see Figure 5J for quantification), indicating that calnexin
partially binds to N-glycans of the a1(A322D) subunit. SAHA
treatment did not significantly change the ratio of immuno-
precipitated calnexin/N38Q/N138Q mutant a1(A322D) subunit
(Figure 5I, cf. lane 3 to lane 2, see Figure 5J for quantification),
indicating that a glycan-binding activity of calnexin is important
in regulating SAHA’s function to promote a1(A322D) subunit
folding.
SAHA Decreases HDAC7 Protein Level and HDAC7
Knockdown Increases Protein Level of Cell Surface
a1(A322D) Subunit and BiP
SAHA was reported to selectively suppress HDAC7 expression
(Dokmanovic et al., 2007), andHDAC7playsacentral role in regu-
lating SAHA’s function of rescuing mutant CFTR (Hutt et al.,
2010). However, how HDAC7 influences protein folding in the
ER was not well understood. Therefore, we continued to test
the role of HDAC7 in restoring GABAA receptor function, possibly
by regulatingBiP level. SAHAdecreasedHDAC7protein level in a
dose-dependent manner from 0.5 to 10 mM in HEK293 cells sta-
bly expressing a1(A322D)b2g2GABAA receptors (Figures 6A and
6B). HDAC7 knockdown (87% knockdown efficiency) signifi-
cantly increased the protein level of cell surface a1(A322D) sub-
unit (Figures 6C and 6D) and total a1(A322D) subunit (data
not shown), indicating that HDAC7 negatively regulated the pro-
tein synthetic load of the a1(A322D) subunit. Knockdown of
HDAC7 significantly increased BiP protein level in HEK293 cells8, December 19, 2013 ª2013 Elsevier Ltd All rights reserved 1463
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Figure 5. SAHA Enhances the Interaction between Calnexin and the a1 Subunit, and Calnexin Promotes the a1 Subunit Folding in the ER
(A and B) SAHA treatment (2.5 mM, 24 hr) enhances the interaction between the a1 subunit and calnexin in HEK293 cells stably expressing WT a1b2g2 or
a1(A322D)b2g2 GABAA receptors. Quantification of the relative intensity of calnexin/ a1 is shown in (B).
(C) Reverse immunoprecipitation confirms that SAHA treatment (2.5 mM, 24 hr) enhances the interaction between the a1(A322D) subunit and calnexin.
(D–F) CNX overexpression increases endo H-resistant post-ER glycoform of the a1 subunit (n = 3) (D). PNGase F treatment serves as a control for unglycosylated
a1 subunit. Quantification of the ratio of endo H-resistant / total a1 subunit bands is shown in (E), and quantification of CNX overexpression is shown in (F). EV,
empty vector.
(G and H) SAHA treatment (2.5 mM, 24 hr) enhances the interaction between the a1(A322D) subunit and overexpressed calnexin in HEK293 cells expressing
a1(A322D)b2g2 GABAA receptors (G). Quantification of the blots is shown in (H).
(I and J) Calnexin interacts with the a1(A322D) subunit in a glycan-dependent way. The N38Q/N138Q mutations in the a1(A322D) subunit disrupt the interaction
between the N-glycans in the a1(A322D) subunit and calnexin (I). SAHA treatment does not change the interaction between the N38Q/N138Q mutant a1(A322D)
subunit and calnexin (I). Quantification of the blots is shown in (J). NS, not significant.
Each data point in (B), (C), (E), (F), (H), and (J) is reported as mean ± SEM. *p < 0.05
Chemistry & Biology
SAHA Enhances Mutant GABAA Receptor Proteostasisexpressing a1(A322D)b2g2 GABAA receptors (Figures 6C and
6D), indicating that HDAC7 suppression could enhance the
surface expression of the a1(A322D) subunit partially by upregu-
lating BiP expression. This also implies that SAHA treatment
increased the BiP level by suppressing HDAC7 without an
apparent induction of the IRE1 arm of the UPR (Figure 3D).1464 Chemistry & Biology 20, 1456–1468, December 19, 2013 ª2013DISCUSSION
Here, we reported that SAHA enhances epilepsy-associated
a1(A322D)b2g2 GABAA receptor proteostasis. The plasma con-
centration of SAHA in the context of phase I clinical trials
exceeded 2.5 mM (Kelly et al., 2003). Thus, our finding that atElsevier Ltd All rights reserved
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Figure 6. Effect of SAHA on HDAC7 in
HEK293 Cells Expressing a1(A322D)b2g2
GABAA Receptors
(A and B) SAHA treatment (24 hr) decreases the
HDAC7 protein level in a dose-dependent manner
(A). Quantification is shown in (B).
(C and D) HDAC7 knockdown increases the pro-
tein level of cell surface a1(A322D) subunit and
BiP. HEK293 cells expressing a1(A322D)b2g2
GABAA receptors were transfected with siRNA
against HDAC7 or nontargeting (NT) control for
48 hr before protein analysis (C). Quantification is
shown in (D).
Each data point in (B) and (D) is reported asmean ±
SEM. *p < 0.05
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SAHA Enhances Mutant GABAA Receptor Proteostasis2.5 mM, SAHA effectively partially restored epilepsy-associated
a1(A322D)b2g2 GABAA receptor proteostasis (Figures 1 and 2)
may be clinically significant. As SAHA at this concentration
only restores a GABA-induced maximal current in HEK293 cells
expressing a1(A322D)b2g2 receptors to 10% of that in HEK293
cells expressing WT receptors, it needs to be evaluated whether
this will have a significant in vivo effect. Seizures are threshold
events. A small change in GABAA receptor functions, for
example by the application of a GABAA receptor antagonist
called bicuculline, can change the seizure threshold (Hentschke
et al., 2006). The conversion of an essentially nonfunctional
a1(A322D)b2g2 receptor to a receptor with 10% WT receptor
function may change a seizure threshold to a clinically beneficial
level. SAHA did not rescue trafficking-deficient mutant hERG
channel folding and trafficking (unpublished data), indicating
that SAHA has certain selectivity in enhancing GABAA receptor
folding. As SAHA crosses the blood-brain barrier (Hockly et al.,
2003), is well tolerated in our cell culture study and in clinical
trials, and only 8% of genes are significantly changed after
SAHA treatment in numerous cell lines by DNA microarray anal-
ysis (Glaser et al., 2003), this makes it a promising test candidate
for the amelioration of idiopathic epilepsy resulting from GABAA
receptor misfolding.
GABAA receptors are heteropentameric receptors. The
missense A322D mutation is in the TM3 domain of the a1 sub-
unit, close to the cytosolic part. The introduction of a negative
charge in TM3 leads to a collapse of the TM3 helix from the ER
membrane, which triggers the misfolding and degradation of
the whole a1(A322D) subunit. SAHA treatment increased the
population of properly folded a1(A322D) subunits, which will
assemble efficiently with b2 and g2 subunits. Fully assembled
GABAA receptors will be able to traffic to the plasma membraneChemistry & Biology 20, 1456–1468, December 19, 2013 ªfor their function. The A322D mutation in
the a1 subunit has a dominant negative
effect, leading to reduced cell surface
expression of WT a1 subunit as well as
WT a3 subunits by associating with those
WT subunits in the ER and trapping them
in the ER for degradation (Ding et al.,
2010). Therefore, simple introduction of
the WT a1 subunit into patients with the
A322D mutation might not prevent the
seizure symptoms. It might be necessaryto rescue the misfolding behavior of the a1(A322D) subunit in the
ER per se to restore its function.
Although SAHA was reported to enhance proteostasis of
mutant CFTR (Hutt et al., 2010), lysosomal glucocerebrosidase
(Lu et al., 2011), and a1-antitrypsin (Bouchecareilh et al., 2012),
the proposed mechanism was very different. In restoration
of the function of DF508 CFTR, SAHA was shown to mainly
use the HDAC7 pathway without activation of the UPR or heat
shock response; SAHA did not increase the BiP protein level,
and the interaction between CFTR and calnexin was not
explored in CFBE40o- cells stably expressing DF508 CFTR
(Hutt et al., 2010). In restoration of the function of L444P gluco-
cerebrosidase (GCase), SAHA was shown to decrease the inter-
action between L444P GCase and Hsp90, but not Hsp70 or
TCP1; however, the role of SAHA’s effect on ER chaperones
was not explored although the folding of L444P GCase occurs
in the ER (Lu et al., 2011). In restoration of the function of
Z-variant of a1-antitrypsin (Z-a1AT), SAHA was shown to act
by reducing the interaction between Z-a1AT and calnexin, and
calnexin silencing restored Z-a1AT maturation; SAHA did not
increase the BiP protein level in HCT116 cells stably expressing
Z-a1AT (Bouchecareilh et al., 2012). Here, we showed that SAHA
enhanced GABAA receptor folding and trafficking by increasing
the BiP protein level and enhancing the interaction between
the a1(A322D) subunit and calnexin. An increased expression
of BiP by SAHA was not reported in cells expressing other mis-
folded proteins; SAHA increased BiP level by inhibiting HDAC7
(Figure 6C). A decreased interaction between calnexin and the
a1(A322D) subunit was shown to reduce the maturation of the
a1(A322D) subunit (Figure 5I), and calnexin overexpression pro-
moted the a1(A322D) subunit maturation (Figure 5D). This is in
contrast to the Z-a1AT case, indicating that the role of calnexin2013 Elsevier Ltd All rights reserved 1465
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SAHA Enhances Mutant GABAA Receptor Proteostasisin assisting protein folding might depend on its specific client
protein. It was reported that calnexin has a potential acetylation
site at Lys137 (Choudhary et al., 2009); it will be intriguing
to explore how SAHA increased the interaction between
a1(A322D) subunit and calnexin, which might be by inhibiting
HDACs in the ER. The critical involvement of ER chaperones to
assist the folding of the a1 subunit might partially be due to the
topology of the a1 subunit: the a1 subunit has a large 224-resi-
due ER lumen N terminus. This is in contrast to the topology of
CFTR, which has relatively short ER lumen components.
In a biological system, the protein quality control machinery is
finely tuned to meet the demand of protein synthesis, folding,
trafficking and degradation (Balch et al., 2008). Our results
showed that an increased protein load did not lead to an
increased protein trafficking efficiency for misfolding-prone
a1(A322D) subunits (Figure 1I). Similar case was reported:
increasing protein synthesis of R752W hERG channels using
the 4-PBA small molecule did not restore their maturation (Ficker
et al., 2000). Simply overloading newly synthesized misfolding-
prone proteins in the ER itself is not sufficient to enhance their
trafficking efficiency or maturation. Therefore, to rescue a mis-
folding-prone a1(A322D) subunit, it is important to rescue the
misfolding behavior of the a1(A322D) subunit in the ER per se.
SAHA increased the transcriptional level and thus newly syn-
thesized protein load of the a1(A322D) subunit (Figure S1E).
Furthermore, SAHA enhanced the folding and trafficking of the
a1(A322D) subunit posttranslationally by promoting BiP and cal-
nexin-assisted folding in the ER (Figures 1, 4, and 5). Therefore,
SAHA increased both the transcription and the trafficking
efficiency of the a1(A322D) subunit, leading to greater rescue
of functional a1(A322D)b2g2 GABAA receptors on the plasma
membrane (Figure 2) than either effect alone.SIGNIFICANCE
We reported that SAHA, a FDA-approved drug that crosses
the blood-brain barrier, enhances the function of epilepsy-
associated a1(A322D)b2g2 GABAA receptors. The A322D
mutation in the a1 subunit resulted in extensive ERAD of
the a1(A322D) subunit and loss of function of GABAA recep-
tors. SAHA enhanced the folding and trafficking of the
a1(A322D) subunit post-translationally by promoting BiP
and calnexin-assisted folding in the ER in addition to its
role in increasing the transcription of the a1(A322D) subunit.
This significantly restored partial function of a1(A322D)b2g2
GABAA receptors on the plasmamembrane, which suggests
SAHA’s promise to ameliorate ADJME resulting fromGABAA
receptor misfolding. We also reported that both BiP and
calnexin, two abundant ER chaperones, are sufficient to
promote the a1(A322D) subunit folding in the ER. Therefore,
wemight be able to target BiP or calnexin to enhanceGABAA
receptor proteostasis, which might be extended to treat a
number of protein misfolding diseases.EXPERIMENTAL PROCEDURES
Cycloheximide-Chase Assay
HEK293 cells stably expressing a1(A322D)b2g2GABAA receptorswere seeded
at 2.5 3 105 cells per well in six-well plates and incubated at 37C overnight.1466 Chemistry & Biology 20, 1456–1468, December 19, 2013 ª2013Cells were then treated with SAHA for 24 hr prior to cycloheximide-chase.
To stop protein translation, cells were treated with 100 mg/ml cycloheximide
(Ameresco).Cellswere thenchased for the indicated time, harvested, and lysed.
Confocal Immunofluorescence
The labeling of cell surface and total a1 subunits and confocal immunofluores-
cencemicroscopy analysis were performed according to published procedure
(Eshaq et al., 2010). See Supplemental Experimental Procedures for detail.
Biotinylation of Cell Surface Proteins
Cells were plated in 10-cm dishes for surface biotinylation experiments
according to published procedure (Lachance-Touchette et al., 2011). See
Supplemental Experimental Procedures for detail.
Whole-Cell Patch Clamp Electrophysiology Recording
Whole-cell currents were recorded 48 hr post transfection using HEK293 cells
using published procedure (Eshaq et al., 2010). See Supplemental Experi-
mental Procedures for detail.
Quantitative RT-PCR
The relative expression levels of target genes were analyzed using quantitative
RT-PCR according to published procedure (Mu et al., 2008). See Supple-
mental Experimental Procedures for detail.
RT-PCR Analysis of Xbp-1 Splicing
After reverse transcription, PCR reactions were performed using cDNA, Taq
DNA polymerase, and primers against XBP1 and GAPDH (listed in Table
S1). PCR products were separated on a 2.5% agarose gel. Unspliced Xbp-1
yielded a 289 bp amplicon, and spliced Xbp-1 yielded a 263 bp amplicon.
Western Blot Band Intensity Quantification
We used NIH image J software to quantify the western blot band intensity,
following the step-by-step instructions from http://lukemiller.org/index.php/
2010/11/analyzing-gels-and-western-blots-with-image-j. This quantification
method has been widely used (Lafon et al., 2012).
Statistical Analysis
All data are presented as mean ± SEM, and any statistical significance was
calculated using two-tailed Student’s t test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.chembiol.2013.09.020.
ACKNOWLEDGMENTS
We thank the following for their generosity of providing us with plasmids: Pro-
fessor Tohru Mizushima (Kumamoto University) for pcDNA3.1-BiP and
pCR(calreticulin)-HA and Professor Michael Brenner (Harvard Medical School)
for Apr-M8-CNX. This work was supported by the Research Start-up Fund
fromCaseWestern Reserve University School of Medicine, the Epilepsy Foun-
dation of America (225243), and the Clinical Translational Science Collabora-
tive of Cleveland CTSA (UL1RR024989) from the National Center for Research
Resources and the National Center for Advancing Translational Sciences of
the National Institutes of Health.
Received: February 14, 2013
Revised: September 23, 2013
Accepted: September 26, 2013
Published: November 7, 2013
REFERENCES
Adachi, Y., Yamamoto, K., Okada, T., Yoshida, H., Harada, A., and Mori, K.
(2008). ATF6 is a transcription factor specializing in the regulation of quality
control proteins in the endoplasmic reticulum. Cell Struct. Funct. 33, 75–89.Elsevier Ltd All rights reserved
Chemistry & Biology
SAHA Enhances Mutant GABAA Receptor ProteostasisAlder, N.N., and Johnson, A.E. (2004). Cotranslational membrane protein
biogenesis at the endoplasmic reticulum. J. Biol. Chem. 279, 22787–22790.
Balch, W.E., Morimoto, R.I., Dillin, A., and Kelly, J.W. (2008). Adapting proteo-
stasis for disease intervention. Science 319, 916–919.
Bouchecareilh, M., Hutt, D.M., Szajner, P., Flotte, T.R., and Balch, W.E. (2012).
Histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid
(SAHA)-mediated correction of a1-antitrypsin deficiency. J. Biol. Chem. 287,
38265–38278.
Braakman, I., and Bulleid, N.J. (2011). Protein folding and modification in the
mammalian endoplasmic reticulum. Annu. Rev. Biochem. 80, 71–99.
Bradley, C.A., Taghibiglou, C., Collingridge, G.L., and Wang, Y.T. (2008).
Mechanisms involved in the reduction of GABAA receptor alpha1-subunit
expression caused by the epilepsy mutation A322D in the trafficking-compe-
tent receptor. J. Biol. Chem. 283, 22043–22050.
Bukau, B., Weissman, J., and Horwich, A. (2006). Molecular chaperones and
protein quality control. Cell 125, 443–451.
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M.L., Rehman, M., Walther, T.C.,
Olsen, J.V., andMann, M. (2009). Lysine acetylation targets protein complexes
and co-regulates major cellular functions. Science 325, 834–840.
Connolly, C.N., Krishek, B.J., McDonald, B.J., Smart, T.G., and Moss, S.J.
(1996). Assembly and cell surface expression of heteromeric and homomeric
gamma-aminobutyric acid type A receptors. J. Biol. Chem. 271, 89–96.
Cossette, P., Liu, L.D., Brisebois, K., Dong, H.H., Lortie, A., Vanasse,M., Saint-
Hilaire, J.M., Carmant, L., Verner, A., Lu, W.Y., et al. (2002). Mutation of
GABRA1 in an autosomal dominant form of juvenile myoclonic epilepsy. Nat.
Genet. 31, 184–189.
Deuerling, E., and Bukau, B. (2004). Chaperone-assisted folding of newly syn-
thesized proteins in the cytosol. Crit. Rev. Biochem. Mol. Biol. 39, 261–277.
Ding, L., Feng, H.-J., Macdonald, R.L., Botzolakis, E.J., Hu, N., and Gallagher,
M.J. (2010). GABA(A) Receptor alpha 1 Subunit Mutation A322D Associated
with Autosomal Dominant Juvenile Myoclonic Epilepsy Reduces the
Expression and Alters the Composition of Wild Type GABA(A). Receptors. J.
Biol. Chem. 285, 26390–26405.
Dokmanovic, M., Perez, G., Xu, W., Ngo, L., Clarke, C., Parmigiani, R.B., and
Marks, P.A. (2007). Histone deacetylase inhibitors selectively suppress
expression of HDAC7. Mol. Cancer Ther. 6, 2525–2534.
Dong, M., Bridges, J.P., Apsley, K., Xu, Y., andWeaver, T.E. (2008). ERdj4 and
ERdj5 are required for endoplasmic reticulum-associated protein degradation
of misfolded surfactant protein C. Mol. Biol. Cell 19, 2620–2630.
Dougherty, D.A. (2008). Cys-loop neuroreceptors: structure to the rescue?
Chem. Rev. 108, 1642–1653.
Dudek, J., Benedix, J., Cappel, S., Greiner, M., Jalal, C., Mu¨ller, L., and
Zimmermann, R. (2009). Functions and pathologies of BiP and its interaction
partners. Cell. Mol. Life Sci. 66, 1556–1569.
Eshaq, R.S., Stahl, L.D., Stone, R., 2nd, Smith, S.S., Robinson, L.C., and
Leidenheimer, N.J. (2010). GABA acts as a ligand chaperone in the early secre-
tory pathway to promote cell surface expression of GABAA receptors. Brain
Res. 1346, 1–13.
Ficker, E., Thomas, D., Viswanathan, P.C., Dennis, A.T., Priori, S.G.,
Napolitano, C., Memmi, M., Wible, B.A., Kaufman, E.S., Iyengar, S., et al.
(2000). Novel characteristics of a misprocessed mutant HERG channel linked
to hereditary long QT syndrome. Am. J. Physiol.-. Heart C. 279, H1748–H1756.
Flynn, G.C., Pohl, J., Flocco, M.T., and Rothman, J.E. (1991). Peptide-binding
specificity of the molecular chaperone BiP. Nature 353, 726–730.
Frydman, J. (2001). Folding of newly translated proteins in vivo: the role of mo-
lecular chaperones. Annu. Rev. Biochem. 70, 603–647.
Gallagher, M.J., Ding, L., Maheshwari, A., and Macdonald, R.L. (2007). The
GABAA receptor alpha1 subunit epilepsy mutation A322D inhibits transmem-
brane helix formation and causes proteasomal degradation. Proc. Natl. Acad.
Sci. USA 104, 12999–13004.
Gidalevitz, T., Prahlad, V., andMorimoto, R.I. (2011). The stress of protein mis-
folding: from single cells to multicellular organisms. Cold Spring Harb.
Perspect. Biol. 3, a009704.Chemistry & Biology 20, 1456–146Glaser, K.B., Staver, M.J., Waring, J.F., Stender, J., Ulrich, R.G., and
Davidsen, S.K. (2003). Gene expression profiling of multiple histone deacety-
lase (HDAC) inhibitors: defining a common gene set produced by HDAC inhi-
bition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2, 151–163.
Green, W.N., and Millar, N.S. (1995). Ion-channel assembly. Trends Neurosci.
18, 280–287.
Guerriero, C.J., and Brodsky, J.L. (2012). The delicate balance between
secreted protein folding and endoplasmic reticulum-associated degradation
in human physiology. Physiol. Rev. 92, 537–576.
Hartl, F.U., and Hayer-Hartl, M. (2002). Molecular chaperones in the cytosol:
from nascent chain to folded protein. Science 295, 1852–1858.
Hartl, F.U., Bracher, A., and Hayer-Hartl, M. (2011). Molecular chaperones in
protein folding and proteostasis. Nature 475, 324–332.
Hebert, D.N., and Molinari, M. (2007). In and out of the ER: protein folding,
quality control, degradation, and related human diseases. Physiol. Rev. 87,
1377–1408.
Hebert, D.N., and Molinari, M. (2012). Flagging and docking: dual roles for
N-glycans in protein quality control and cellular proteostasis. Trends
Biochem. Sci. 37, 404–410.
Hebert, D.N., Simons, J.F., Peterson, J.R., and Helenius, A. (1995). Calnexin,
calreticulin, and Bip/Kar2p in protein folding. Cold Spring Harb. Symp.
Quant. Biol. 60, 405–415.
Hebert, D.N., Bernasconi, R., and Molinari, M. (2010). ERAD substrates: which
way out? Semin. Cell Dev. Biol. 21, 526–532.
Helenius, A., and Aebi, M. (2004). Roles of N-linked glycans in the endoplasmic
reticulum. Annu. Rev. Biochem. 73, 1019–1049.
Helenius, A., Trombetta, E.S., Hebert, D.N., and Simons, J.F. (1997). Calnexin,
calreticulin and the folding of glycoproteins. Trends Cell Biol. 7, 193–200.
Hentschke, M., Wiemann, M., Hentschke, S., Kurth, I., Hermans-Borgmeyer,
I., Seidenbecher, T., Jentsch, T.J., Gal, A., and Hu¨bner, C.A. (2006). Mice
with a targeted disruption of the Cl-/HCO3- exchanger AE3 display a reduced
seizure threshold. Mol. Cell. Biol. 26, 182–191.
Hockly, E., Richon, V.M., Woodman, B., Smith, D.L., Zhou, X.B., Rosa, E.,
Sathasivam, K., Ghazi-Noori, S., Mahal, A., Lowden, P.A.S., et al. (2003).
Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates
motor deficits in amousemodel of Huntington’s disease. Proc. Natl. Acad. Sci.
USA 100, 2041–2046.
Hutt, D.M., Herman, D., Rodrigues, A.P.C., Noel, S., Pilewski, J.M., Matteson,
J., Hoch, B., Kellner, W., Kelly, J.W., Schmidt, A., et al. (2010). Reduced his-
tone deacetylase 7 activity restores function to misfolded CFTR in cystic
fibrosis. Nat. Chem. Biol. 6, 25–33.
Kelly, W.K., O’Connor, O., Richon, V.M., Curley, T., Richardson, S., Thapi, D.,
Chiao, J.H., Rifkind, R.A., Marks, P.A., and Scher, H.I. (2003). Phase I clinical
trial of an oral histone deacetylase inhibitor: Suberoylanilide hydroxamic acid
(SARA). Clin. Cancer Res. 9, 6245S–6246S.
Krampfl, K., Maljevic, S., Cossette, P., Ziegler, E., Rouleau, G.A., Lerche, H.,
and Bufler, J. (2005). Molecular analysis of the A322D mutation in the GABA
receptor alpha-subunit causing juvenile myoclonic epilepsy. Eur. J.
Neurosci. 22, 10–20.
Lachance-Touchette, P., Brown, P., Meloche, C., Kinirons, P., Lapointe, L.,
Lacasse, H., Lortie, A., Carmant, L., Bedford, F., Bowie, D., and Cossette, P.
(2011). Novel a1 and g2 GABAA receptor subunit mutations in families with
idiopathic generalized epilepsy. Eur. J. Neurosci. 34, 237–249.
Lafon, A., Petty, E., and Pillus, L. (2012). Functional antagonism between Sas3
and Gcn5 acetyltransferases and ISWI chromatin remodelers. PLoS Genet. 8,
e1002994.
Lee, A.H., Iwakoshi, N.N., and Glimcher, L.H. (2003). XBP-1 regulates a subset
of endoplasmic reticulum resident chaperone genes in the unfolded protein
response. Mol. Cell. Biol. 23, 7448–7459.
Lester, H.A., Dibas, M.I., Dahan, D.S., Leite, J.F., and Dougherty, D.A. (2004).
Cys-loop receptors: new twists and turns. Trends Neurosci. 27, 329–336.
Lindquist, S. (1986). The heat-shock response. Annu. Rev. Biochem. 55, 1151–
1191.8, December 19, 2013 ª2013 Elsevier Ltd All rights reserved 1467
Chemistry & Biology
SAHA Enhances Mutant GABAA Receptor ProteostasisLo, W.-y., Lagrange, A.H., Hernandez, C.C., Harrison, R., Dell, A., Haslam,
S.M., Sheehan, J.H., and Macdonald, R.L. (2010). Glycosylation of beta 2
Subunits Regulates GABA(A). Receptor Biogenesis and Channel Gating. J.
Biol. Chem. 285, 31348–31361.
Lu, J., Yang, C., Chen, M., Ye, D.Y., Lonser, R.R., Brady, R.O., and Zhuang, Z.
(2011). Histone deacetylase inhibitors prevent the degradation and restore the
activity of glucocerebrosidase in Gaucher disease. Proc. Natl. Acad. Sci. USA
108, 21200–21205.
Macdonald, R.L., and Olsen, R.W. (1994). GABAA receptor channels. Annu.
Rev. Neurosci. 17, 569–602.
Mu, T.W., Ong, D.S.T., Wang, Y.J., Balch, W.E., Yates, J.R., 3rd, Segatori, L.,
and Kelly, J.W. (2008). Chemical and biological approaches synergize to
ameliorate protein-folding diseases. Cell 134, 769–781.
Okada, T., Yoshida, H., Akazawa, R., Negishi, M., and Mori, K. (2002). Distinct
roles of activating transcription factor 6 (ATF6) and double-stranded RNA-acti-
vated protein kinase-like endoplasmic reticulum kinase (PERK) in transcription
during the mammalian unfolded protein response. Biochem. J. 366, 585–594.
Otero, J.H., Liza´k, B., and Hendershot, L.M. (2010). Life and death of a BiP
substrate. Semin. Cell Dev. Biol. 21, 472–478.
Ru¨diger, S., Germeroth, L., Schneider-Mergener, J., and Bukau, B. (1997).
Substrate specificity of the DnaK chaperone determined by screening cellu-
lose-bound peptide libraries. EMBO J. 16, 1501–1507.1468 Chemistry & Biology 20, 1456–1468, December 19, 2013 ª2013Rutkevich, L.A., and Williams, D.B. (2011). Participation of lectin chaperones
and thiol oxidoreductases in protein folding within the endoplasmic reticulum.
Curr. Opin. Cell Biol. 23, 157–166.
Schro¨der, M., and Kaufman, R.J. (2005). The mammalian unfolded protein
response. Annu. Rev. Biochem. 74, 739–789.
Simons, J.F., Ferro-Novick, S., Rose, M.D., and Helenius, A. (1995). BiP/Kar2p
serves as a molecular chaperone during carboxypeptidase Y folding in yeast.
J. Cell Biol. 130, 41–49.
Skach, W.R. (2009). Cellular mechanisms of membrane protein folding. Nat.
Struct. Mol. Biol. 16, 606–612.
Smith, M.H., Ploegh, H.L., and Weissman, J.S. (2011). Road to ruin: targeting
proteins for degradation in the endoplasmic reticulum. Science 334, 1086–
1090.
Ushioda, R., Hoseki, J., Araki, K., Jansen, G., Thomas, D.Y., and Nagata, K.
(2008). ERdj5 is required as a disulfide reductase for degradation of misfolded
proteins in the ER. Science 321, 569–572.
Vembar, S.S., and Brodsky, J.L. (2008). One step at a time: endoplasmic retic-
ulum-associated degradation. Nat. Rev. Mol. Cell Biol. 9, 944–957.
Walter, P., and Ron, D. (2011). The unfolded protein response: from stress
pathway to homeostatic regulation. Science 334, 1081–1086.Elsevier Ltd All rights reserved
